Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges
The rapid transformation in rare disease treatment, driven by advances in genetic medicine and diagnostics, underscores the urgent need for access to these innovative therapies. With over 10,000 identified rare diseases globally, 80% of which are genetic, the current therapeutic landscape indicates...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Molecular Therapy: Methods & Clinical Development |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050124002195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595337306439680 |
|---|---|
| author | Diane Berry Carolyn Hickey Lisa Kahlman James Long Christina Markus Caitlin K. McCombs |
| author_facet | Diane Berry Carolyn Hickey Lisa Kahlman James Long Christina Markus Caitlin K. McCombs |
| author_sort | Diane Berry |
| collection | DOAJ |
| description | The rapid transformation in rare disease treatment, driven by advances in genetic medicine and diagnostics, underscores the urgent need for access to these innovative therapies. With over 10,000 identified rare diseases globally, 80% of which are genetic, the current therapeutic landscape indicates that only 5% of these conditions have FDA-approved treatments. This article examines the critical logistical challenges in commercializing and paying for gene therapies for rare diseases. It highlights the importance of considering innovative payment models, addressing patient portability issues, and aligning payer coverage policies with FDA-approved indications. It emphasizes the need to account for the broader value of gene therapies, incorporate input from disease-specific clinical experts in payer coverage decisions, and reduce administrative barriers to coverage. By adopting a multifaceted approach, we can foster a more supportive environment for the sustainable delivery of gene therapies, significantly improving the lives of patients with rare genetic disorders while rewarding and driving continued innovation. |
| format | Article |
| id | doaj-art-8920936729fe40cfa65a83148851f59a |
| institution | Kabale University |
| issn | 2329-0501 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Methods & Clinical Development |
| spelling | doaj-art-8920936729fe40cfa65a83148851f59a2025-01-19T06:26:08ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012025-03-01331101403Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challengesDiane Berry0Carolyn Hickey1Lisa Kahlman2James Long3Christina Markus4Caitlin K. McCombs5Sarepta Therapeutics, Inc., Cambridge, MA, USA; Government Affairs and Policy, Sarepta Therapeutics, Inc., Cambridge, MA, USAGovernment Affairs and Policy, Sarepta Therapeutics, Inc., Cambridge, MA, USAPublic Policy and Public Affairs, Ultragenyx Pharmaceutical, Inc., Novato, CA, USAClinical Pharmacy Services, DK Pierce, Zionsville, IN, USAFDA and Life Sciences Practice, King & Spalding, Washington, DC, USAAmerican Society of Gene and Cell Therapy, Waukesha, WI, USA; Corresponding author: Caitlin K. McCombs, American Society of Gene and Cell Therapy, Waukesha, WI, USA.The rapid transformation in rare disease treatment, driven by advances in genetic medicine and diagnostics, underscores the urgent need for access to these innovative therapies. With over 10,000 identified rare diseases globally, 80% of which are genetic, the current therapeutic landscape indicates that only 5% of these conditions have FDA-approved treatments. This article examines the critical logistical challenges in commercializing and paying for gene therapies for rare diseases. It highlights the importance of considering innovative payment models, addressing patient portability issues, and aligning payer coverage policies with FDA-approved indications. It emphasizes the need to account for the broader value of gene therapies, incorporate input from disease-specific clinical experts in payer coverage decisions, and reduce administrative barriers to coverage. By adopting a multifaceted approach, we can foster a more supportive environment for the sustainable delivery of gene therapies, significantly improving the lives of patients with rare genetic disorders while rewarding and driving continued innovation.http://www.sciencedirect.com/science/article/pii/S2329050124002195 |
| spellingShingle | Diane Berry Carolyn Hickey Lisa Kahlman James Long Christina Markus Caitlin K. McCombs Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges Molecular Therapy: Methods & Clinical Development |
| title | Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges |
| title_full | Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges |
| title_fullStr | Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges |
| title_full_unstemmed | Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges |
| title_short | Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges |
| title_sort | ensuring patient access to gene therapies for rare diseases navigating reimbursement and coverage challenges |
| url | http://www.sciencedirect.com/science/article/pii/S2329050124002195 |
| work_keys_str_mv | AT dianeberry ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges AT carolynhickey ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges AT lisakahlman ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges AT jameslong ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges AT christinamarkus ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges AT caitlinkmccombs ensuringpatientaccesstogenetherapiesforrarediseasesnavigatingreimbursementandcoveragechallenges |